Growth Stock Watch: NxStage Medical, Inc. (NASDAQ:NXTM) - Enterprise Leader
NxStage Medical, Inc. (NASDAQ:NXTM) has been given a positive Growth Style Score by Zacks Research. The Growth score analyzes the growth prospects for a company in addition to analyzing company financials. The score takes into account various measures of the Income Statement, Cash Flow Statement and Balance Sheet to achieve a ranking of A-F, where A indicates that the stock has the best growth characteristics likely to outperform the market.
Analysts tracked by Zacks have given NxStage Medical, Inc. a mean long term growth estimate of 18.33. This number is based on sales and earnings over the next 3-5 years, calculated on a consensus basis. On a shorter term basis, analysts have a projected price target of $21 on the equity. This is a one-year consensus target based on 4 sell-side analysts providing estimates. The firm with the most bullish sentiment sees the stock reaching $24 while the most conservative has the target set at $15. Sell-side firms use a variety of different terms such a Buy, Sell and Hold to rate their outlook on stocks. Using a simplified scale where Strong Buy equals 1 and Strong Sell equals 5, the consensus simplified rating for NxStage Medical, Inc. is 2. NxStage Medical, Inc. (NASDAQ:NXTM) is next slated to report quarterly results on 2015-08-06 where the Street is anticipating earnings per share of $-0.1. Most recently the firm reported earnings of $0 for the period ending on 2015-03-31. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
WEDNESDAY, June 24, 2015 (HealthDay News) -- More than one-third of kidney dialysis patients in the United States live in poor neighborhoods, a study finds.
Kidney dialysis rates in the United States are higher in poor neighborhoods, and they're increasing in those areas, the 15-year analysis shows. Dialysis is used to treat people with kidney failure.
Researchers analyzed U.S. Centers for Medicare and Medicaid Services data to assess overall dialysis rates and those in poor areas, defined as having a a zip code where at least 20 percent of people live below the federal poverty line.
The results showed that 27.4 percent of adults who began dialysis between 1995 and 2004 lived in poor neighborhoods, compared with about 11 percent of adults in the general population.
Those percentages increased to 34 percent and 12.5 percent, respectively, between 2005 and 2010, said the researchers from Loyola University Chicago Stritch School of Medicine.
The study was published recently in the journal Hemodialysis International.
The researchers said it's not clear why kidney failure and dialysis rates are higher in poor neighborhoods. Possible reasons could be less access to health care, greater exposure to environmental toxins and lifestyle habits, they said.
Future studies of kidney failure rates should examine long-term trends in poverty at the individual level and in smaller geographic areas, said corresponding author Dr. Holly Kramer and colleagues.
"The collection of such data may help track national and local trends in poverty status and be used to develop policies for improving health outcomes and disease prevention," they wrote.
More information
The National Kidney Foundation has more about dialysis.
Hold Smartphones Away from Cardiac Devices - Renal and Urology News
June 24, 2015
Risk is low; however, heart patients are advised to keep phones away from chest pockets.
(HealthDay News) -- Smartphones should be kept a safe distance from implanted cardiac devices like pacemakers and defibrillators, in the rare chance that signaling interference occurs, according to new research. The findings were scheduled to be presented Monday at the joint meeting of the European Heart Rhythm Association of the European Society of Cardiology and Cardiostim in Milan.
Researchers tracked the effects of smartphones on 308 patients with an implanted cardiac device. Participants were exposed to the electromagnetic field of 3 common smartphones: the Samsung Galaxy 3; Nokia Lumia; and HTC One XL. These phones were placed on the patients' skin directly above their heart device. After being connected to a radio communication tester that functions like a mobile network station, the researchers analyzed how activities such as connecting calls, ringing, talking, and hanging up all affected the cardiac devices. Electrocardiograms recorded continuously.
After conducting more than 3,400 tests on EMI, the researchers found that only 1 of the patients was affected by interference caused by smartphones. This person had a magnetic resonance imaging-compatible implanted defibrillator, which misinterpreted electromagnetic waves from the Nokia and HTC smartphones. The new findings suggest that interference between smartphones and cardiac devices is uncommon; however, it "can occur, so the current recommendations on keeping a safe distance should be upheld." lead author Carsten Lennerz, M.D., a cardiology resident at the German Heart Centre in Munich, said in a news release from the European Society of Cardiology.
"Nearly everyone uses smartphones and there is the possibility of interference with a cardiac device if you come too close," senior author Christof Kolb, M.D., prior head of electrophysiology at the German Heart Centre, said in the news release. "Patients with a cardiac device can use a smartphone," Kolb said. "But they should not place it directly over the cardiac device. That means not storing it in a pocket above the cardiac device. They should also hold their smartphone to the ear opposite to the side of the device implant."
This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Global Markets Direct's, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)'s therapeutic pipeline. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.
For More Information visit @ http://www.radiantinsights.com/research/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h1-2015
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
< PrevNext >
NxStage Kicks Off 10th Anniversary of Innovation Milestone with Summer-Long ... - PR Newswire (press release)
NxStage Celebrates 10th Anniversary
LAWRENCE, Mass., June 24, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is proud to announce that today is the 10th year anniversary of the Food and Drug Administration's (FDA) clearance of its revolutionary System One™. In recognition of this milestone, the Company is celebrating the personal achievements of patients performing home hemodialysis (HHD) with the NxStage® System One. This summer-long celebration will promote the significant life changing benefits made possible with HHD, feature the System One's market leading technology, and promote NxStage's decade long role in helping patients regain control of their lives.
Over ten years ago, NxStage set out to innovate a dialysis treatment paradigm that could provide patients with access to more therapy options to meet both their clinical and lifestyle needs. Today, NxStage's System One is the first and only portable dialysis machine that enables patients to perform dialysis in their homes or while traveling, during the day or at night while sleeping. It has been used to perform over ten million treatments on thousands of patients around the world, changing the way patients and clinicians think about hemodialysis.
Jenna Smith is a 29-year-old Seattle resident with a rare condition called Dense Deposit Disease (DDD) which led to her kidney failure. Smith tried a range of treatment options for kidney failure, including a failed transplant from her father and in-center hemodialysis. She chose HHD with the System One ten years ago because the in-center treatment regimen posed challenges for her individual healthcare needs due to the lack of frequency and flexibility of the therapy. While treating with the System One, Smith graduated from the University of Iowa, moved to Oregon, earned her graduate degree, and now works in 3D digital modeling at an engineering firm in Seattle.
"The number of personal goals I've achieved over the past 10 years would not have been possible without the NxStage System One," said Smith. "I'm extremely thankful to have found home hemodialysis because my treatment fits into my life whenever and wherever I want, instead of the other way around."
"A decade after launching the first System One, we continue to redefine renal care by allowing patients to take back control of their lives with home hemodialysis treatments tailored to their own needs," said Joseph E. Turk, President of NxStage. "We're committed to improving the lives of dialysis patients with more groundbreaking innovations in the years ahead."
Visit our Facebook page www.facebook.com/NxStage to read more inspiring patient stories throughout the summer. If you would like to share your personal achievements while using the System One please email our patient marketing team at
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
For more information about the System One, home hemodialysis or home nocturnal hemodialysis, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
Additional Risks Associated with Nocturnal Home Hemodialysis Therapy
The NxStage System One may be used at night while the patient and care partner are sleeping. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Ancillary anticoagulant infusion pumps and fluid leak detection devices may be used to decrease certain risks for home hemodialysis treatments performed at any time, but NxStage requires the use of fluid leak detectors to identify leaks from the vascular access, Cycler and Cartridge when performing nocturnal therapy with the NxStage System One.
About the NxStage System One The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: (978) 332-5923
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
NxStage Celebrates 10th Anniversary
